Mohit Jain, MD
Interventional Cardiology · Spokane, WANPI 1659557254
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,375 of the $98,131 with a category attached, or 64.6%. Boehringer Ingelheim accounts for 66.0% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $24,124 and has fallen 51.7% since, to $11,640 in 2025. Among interventional cardiology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $274.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$65K
- Abbott$14K
- Lilly USA, LLC$12K
- Boston Scientific$4K
- Medical Device Business Services, Inc.$551
- Johnson & Johnson$397
- plus $2K from 17 others
What the payments were for
- Consulting fees$8,2508%
- Speaking & faculty fees$63,37565%
- Travel & lodging$16,45917%
- Food & beverage$10,04710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 78 | $64,805 |
| Abbott | 53 | $13,945 |
| Lilly USA, LLC | 7 | $12,425 |
| Boston Scientific | 119 | $4,155 |
| Medical Device Business Services, Inc. | 26 | $551 |
| Johnson & Johnson | 13 | $397 |
| Novo Nordisk | 3 | $264 |
| Novartis | 7 | $260 |
| Pfizer | 22 | $258 |
| AstraZeneca | 2 | $157 |
| Medtronic(2 entities) | 2 | $140 |
| Philips North America LLC | 2 | $139 |
| Edwards Lifesciences | 6 | $133 |
| Amgen | 5 | $108 |
| Cardiva Medical, Inc. | 3 | $105 |
| Kestra Medical Technology Services, Inc. | 1 | $100 |
| Merck | 2 | $43 |
| Chiesi USA, Inc. | 2 | $38 |
| Abiomed | 1 | $33 |
| Penumbra, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Baylis Medical Company Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$76,219
- AMPLATZER AMULET$10,819
- JETi All In One Non-Sterile Kit$1,750
- GENERAL - THERAPIES$747
- WATCHMAN FLX$647
- XARELTO$257
- Watchman$223
- WATCHMAN Access System$140
- Carto 3$140
- LEQVIO$135
- ENTRESTO$135
- CARDIOMEMS$127
- Wegovy$125
- Ozempic$125
- SYMPLICITY G3$125
- Assure WCD$100
How this compares
$98,131 in reported general payments places this provider in the 90th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 118 | $148,908 |
| EliquisApixaban | 107 | $136,013 |
| XareltoRivaroxaban | 112 | $106,793 |
| EntrestoSacubitril/Valsartan | 45 | $41,407 |
| FarxigaDapagliflozin Propanediol | 23 | $13,247 |
| Repatha SyringeEvolocumab | 17 | $12,478 |
| Repatha SureclickEvolocumab | 12 | $11,203 |
| Praluent PenAlirocumab | 16 | $9,572 |
| Propranolol Hcl ErPropranolol Hcl | 31 | $3,146 |
| Eplerenone | 37 | $3,053 |
| Diltiazem 12hr ErDiltiazem Hcl | 19 | $2,702 |
| Nebivolol Hcl | 56 | $2,579 |
| Metoprolol Succinate | 142 | $2,366 |
| Atorvastatin Calcium | 195 | $2,358 |
| Clonidine | 16 | $2,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $64,805 | $148,908118 claims |
| PfizerEliquis | $258 | $136,013107 claims |
| Johnson & JohnsonXarelto | $397 | $106,793112 claims |
| NovartisEntresto | $260 | $41,40745 claims |
| AstraZenecaFarxiga | $157 | $13,24723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 125 interventional cardiology providers in Washington.
Other interventional cardiology in Spokane
- Michael RingSpokane$47K
- Joel GallowaySpokane$12K
- Jonathan HansenSpokane$10K
- Philip HuberSpokane$10K
- Dieter LubbeSpokane$7K
- Timothy BallSpokane$6K
- Brydan CurtisSpokane$5K
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Robert RileyBellevue$431K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.